Aravive initiated with a Buy at EF Hutton

EF Hutton analyst Tony Butler initiated coverage of Aravive with a Buy rating and $10 price target. Aravive’s lead compound, batiraxcept, targets the GAS6/AXL pathway known to be involved in activating signals that promote malignant tumor progression in multiple tumor types, Butler tells investors in a research note. The analyst says this pathway is important for cancer metastasis, immune escape, and drug tolerance.